WINTON GROUP Ltd Sells 8,900 Shares of Vericel Co. (NASDAQ:VCEL)

WINTON GROUP Ltd lessened its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 36.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 15,340 shares of the biotechnology company's stock after selling 8,900 shares during the period. WINTON GROUP Ltd's holdings in Vericel were worth $842,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Arcadia Investment Management Corp MI acquired a new position in shares of Vericel in the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC boosted its stake in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock worth $70,000 after acquiring an additional 1,058 shares in the last quarter. Geneos Wealth Management Inc. grew its holdings in shares of Vericel by 826.6% in the 4th quarter. Geneos Wealth Management Inc. now owns 2,511 shares of the biotechnology company's stock worth $138,000 after acquiring an additional 2,240 shares during the last quarter. Quantbot Technologies LP acquired a new stake in shares of Vericel during the third quarter worth $146,000. Finally, KBC Group NV lifted its holdings in shares of Vericel by 82.5% during the fourth quarter. KBC Group NV now owns 2,707 shares of the biotechnology company's stock valued at $149,000 after purchasing an additional 1,224 shares during the last quarter.

Analyst Ratings Changes

VCEL has been the subject of a number of analyst reports. StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a research note on Saturday, March 8th. Stephens reissued an "overweight" rating and set a $65.00 price target on shares of Vericel in a research report on Wednesday, January 15th. Truist Financial reaffirmed a "buy" rating and set a $61.00 target price (down previously from $67.00) on shares of Vericel in a research note on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $60.00 price target on shares of Vericel in a research report on Friday, February 28th. Finally, Canaccord Genuity Group lifted their target price on shares of Vericel from $64.00 to $67.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $62.29.

Remove Ads

Vericel Stock Performance

Shares of VCEL traded down $1.54 during trading hours on Tuesday, hitting $43.08. 421,168 shares of the company were exchanged, compared to its average volume of 378,419. The firm's 50 day moving average is $52.94 and its 200-day moving average is $51.79. Vericel Co. has a 52 week low of $39.12 and a 52 week high of $63.00. The company has a market cap of $2.16 billion, a PE ratio of 718.12 and a beta of 1.78.

Insider Activity

In related news, CEO Dominick Colangelo sold 26,592 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the completion of the transaction, the chief executive officer now owns 259,997 shares of the company's stock, valued at approximately $11,902,662.66. The trade was a 9.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jonathan Siegal sold 1,092 shares of the firm's stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total value of $67,693.08. Following the completion of the sale, the insider now directly owns 1,206 shares in the company, valued at $74,759.94. This trade represents a 47.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,092 shares of company stock valued at $1,683,582 over the last 90 days. 5.20% of the stock is currently owned by company insiders.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.